Spotlight On: Rituxan® (Rituximab) / Truxima® (Rituximab-Abbs) / Ruxience® (Rituximab-Pvvr) / Riabni™ (Rituximab-Arrx) - March 2026

Why It Matters

Patent claim volatility threatens market exclusivity for rituximab biosimilars, influencing pricing and access in oncology and autoimmune therapies.

Key Takeaways

• Rituximab patents face simultaneous IPR and litigation challenges.
• Claims counted per case inflate perceived patent exposure.
• IPR counts ignore §102 vs §103 distinction.
• Multiple disputes may delay biosimilar entry.
• Stakeholders monitor claim metrics for strategic decisions.

Pulse Analysis

The recent surge in Inter‑Partes Review (IPR) filings against rituximab patents reflects a broader industry push to dismantle barriers for biosimilar entrants. IPR, a USPTO‑administered proceeding, allows third parties to contest the validity of patent claims on grounds such as lack of novelty (§102) or obviousness (§103). By aggregating claim counts across each IPR, challengers can illustrate the breadth of vulnerability, even though the same claim may appear in multiple reviews. This methodological nuance is crucial for investors and legal teams assessing the true risk to the patent estate.

In parallel, federal litigations continue to target the same suite of rituximab patents, with each complaint enumerating alleged infringing claims. The reporting practice of counting claims per lawsuit, rather than per unique patent, amplifies the perceived scale of litigation. For pharmaceutical companies, this creates a dual‑front pressure: defending patents in court while simultaneously confronting USPTO challenges. The outcome of these proceedings will dictate the timeline for biosimilar competitors like Truxima® and Ruxience® to capture market share, potentially reshaping pricing dynamics in oncology and autoimmune disease treatment.

Strategically, the overlapping IPR and litigation landscape underscores the importance of robust patent portfolio management. Companies must prioritize claim drafting, monitor prior art, and consider settlement pathways to mitigate prolonged uncertainty. For market analysts, tracking the number of distinct claims under dispute—rather than the inflated aggregate—offers a clearer signal of patent strength and the likelihood of future biosimilar approvals. Ultimately, the resolution of these challenges will impact revenue streams, R&D investment, and patient access to cost‑effective therapies.